Skip to main content
Log in

Cystemustine in recurrent high grade glioma

  • Clinical–patient studies
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

An Erratum to this article was published on 23 June 2006

An Erratum to this article was published on 23 June 2006

Summary

In this study, we have assessed the efficacy of a nitrosourea, cystemustine, in treating patients with recurrent high grade glioma with overall survival analysis as primary end-point.

Forty-eight patients with recurrent high grade glioma (24 glioblastomas, 17 astrocytomas and 5 oligodendrogliomas) were treated every 2 weeks with 60 mg/m2 cystemustine by a 15 min-infusion. The median number of treatment cycles was 4 (range 1–17).

The median overall survival was 8.3 months (range 1–97) and the 6- and 12-month overall survival rates were 55.3% (95% CI, 41.3–68.6%) and 29.8% (95% CI, 18.6–44.0%), respectively. The objective response rate was 18.8% (95% CI, 7.7–29.9%), and 54.2% of patients had stable disease (95% CI, 40.1–68.3%). Multivariate analysis showed that WHO performance status, histology and response to cystemustine were significant prognostic factors for survival of patients with recurrent glioma.

In conclusion, cystemustine has encouraging activity for patients with recurrent high grade glioma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP, Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults Cancer 71(8): 2585–2597, 1993

    Article  PubMed  CAS  Google Scholar 

  2. Stewart LA, Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. (Review) Lancet 359(9311): 1011–1018, 2002

    Article  PubMed  CAS  Google Scholar 

  3. Moser R, Surgery for glioma relapse : factors that influence a favourable outcome Cancer 62: 381–390, 1988

    Article  PubMed  CAS  Google Scholar 

  4. Laing RW, Warrington AP, Graham J, et al., Efficacy and toxicity of fractionated stereotactic radiotherapy in the treatment of recurrent gliomas (phase I/II study) Radiother Oncol 27: 22–39, 1993

    Article  PubMed  CAS  Google Scholar 

  5. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J II, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA, Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery N Engl J Med 303(23): 1323–1329, 1980

    Article  PubMed  CAS  Google Scholar 

  6. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, Wilson CB, Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report Int J Radiat Oncol Biol Phys 18(2): 321–324, 1990

    PubMed  CAS  Google Scholar 

  7. Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, Mealey J Jr, Odom GL, Paoletti P, Ransohoff J 2nd, Robertson JT, Selker RG, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA, Comparisons of carmustine, procarbazine, high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma Cancer Treat Rep 67(2): 121–132, 1983

    PubMed  CAS  Google Scholar 

  8. Madelmont JC, Godeneche D, Parry D, Duprat J, Chabard JL, Plagne R, Mathe G, Meyniel G, New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results J Med Chem 28(9): 1346–1350, 1985

    Article  PubMed  CAS  Google Scholar 

  9. Godeneche D, Madelmont JC, Moreau MF, Duprat J, Chabard JL, Plagne R, Meyniel G, Metabolic disposition of 2-chloroethyl nitrosocarbamoylcystamine in rats Drug Metab Dispos 13(2): 220–226, 1985

    PubMed  CAS  Google Scholar 

  10. Roche H, Cure H, Adenis A, Fargeot P, Terret C, Lentz MA, Madelmont JC, Fumoleau P, Hanausk A, Chollet P, Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adults J Neurooncol 49(2):141–145, 2000

    Article  PubMed  CAS  Google Scholar 

  11. Daumas-Duport C, Grading of astrocytoma : a simple and reproducible method Cancer 62: 2252–2265, 1988

    Article  PubMed  Google Scholar 

  12. Kaplan EL, Meier P, Non parametric estimation for incomplete observation J Am Stat Assoc 53: 457–481, 1958

    Article  Google Scholar 

  13. Cox DR, Regression models and lifes tables J R Stat Soc 34:187–202, 1972

    Google Scholar 

  14. Tatter SB, Recurrent malignant glioma in adults.(Review) Curr Treat Options Oncol 3(6): 509–524, 2002

    Article  PubMed  Google Scholar 

  15. Huncharek M, Muscat J, Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients Anticancer Res. 18(2B): 1303–1311, 1998

    PubMed  CAS  Google Scholar 

  16. Chang SM, Theodosopoulos P, Lamborn K, Malec M, Rabbitt J, Page M, Prados MD, Temozolomide in the treatment of recurrent malignant glioma Cancer 100(3): 605–611, 2004

    Article  PubMed  CAS  Google Scholar 

  17. Brandes AA, Tosoni A, Amista P, Nicolardi L, Grosso D, Berti F, Ermani M, How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial Neurology 63(7): 1281–1284, 2004

    PubMed  CAS  Google Scholar 

  18. Frenay M, Giroux B, Khoury S, Derlon JM, Namer M, Phase II study of fotemustine in recurrent supratentorial malignant gliomas Eur J Cancer 27(7):852–856, 1991

    Article  PubMed  CAS  Google Scholar 

  19. Malhaire JP, Lucas B, Simon H, Person H, Dam-Hieu P, Labat JP, Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas Bull Cancer 86(3): 289–294, 1999

    PubMed  CAS  Google Scholar 

  20. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, et al., Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas The Polymer-brain Tumor Treatment Group Lancet 345(8956): 1008–1012, 1995

    Article  PubMed  CAS  Google Scholar 

  21. Kappelle AC, Postma TJ, Taphoorn MJ, Groeneveld GJ, van den Bent MJ, van Groeningen CJ, Zonnenberg BA, Sneeuw KC, Heimans JJ, PCV chemotherapy for recurrent glioblastoma multiforme Neurology 56(1): 118–120, 2001

    PubMed  CAS  Google Scholar 

  22. Prados MD, Yung WK, Fine HA, Greenberg HS, Junck L, Chang SM, Nicholas MK, Robins HI, Mehta MP, Fink KL, Jaeckle KA, Kuhn J, Hess KR, Schold SC Jr, North American Brain Tumor Consortium study. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study Neuro-oncol 6(1): 33–37, 2004

    Article  PubMed  CAS  Google Scholar 

  23. Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf CB, Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas J Clin Oncol 21(12):2299–2304, 2003

    Article  PubMed  CAS  Google Scholar 

  24. Harris MT, Rosenthal MA, Ashley DL, Cher L, An Australian experience with temozolomide for the treatment of recurrent high grade gliomas J Clin Neurosci 8(4): 325–327, 2001

    Article  PubMed  CAS  Google Scholar 

  25. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA, A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83(5): 588–593, 2000

    Article  PubMed  CAS  Google Scholar 

  26. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, Antonadou D, Saris G, Beroukas K, Karageorgis P, Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme J Clin Oncol 23(10): 2372–2377, 2005

    Article  PubMed  CAS  Google Scholar 

  27. Barrie M, Couprie C, Dufour H, Figarella-Branger D, Muracciole X, Hoang-Xuan K, Braguer D, Martin PM, Peragut JC, Grisoli F, Chinot O, Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme Ann Oncol 16(7): 1177–1184, 2005

    Article  PubMed  CAS  Google Scholar 

  28. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352(10): 987–996, 2005

    Article  PubMed  CAS  Google Scholar 

  29. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O’Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999 Sep; 17(9): 2762–2771. Erratum in: J Clin Oncol 17(11): 3693, 1999

    Google Scholar 

  30. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK, Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17(8):2572–2578, 1999

    PubMed  CAS  Google Scholar 

  31. Puduvalli VK, Hashmi M, McAllister LD, Levin VA, Hess KR, Prados M, Jaeckle KA, Yung WK, Buys SS, Bruner JM, Townsend JJ, Davis R, Sawaya R, Kyritsis AP, Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival Oncology 65(3):259–266, 2003

    Article  PubMed  Google Scholar 

  32. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN, Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas J Natl Cancer Inst 90(19):1473–1479, 1998

    Article  PubMed  CAS  Google Scholar 

  33. Buckner JC, Factors influencing survival in high-grade gliomas. (Review) Semin Oncol 30(6 Suppl 19):10–14, 2003

    Article  PubMed  Google Scholar 

  34. Grant R, Liang BC, Slattery J, Greenberg HS, Junck L, Chemotherapy response criteria in malignant glioma Neurology 48(5):1336–1340, 1997

    PubMed  CAS  Google Scholar 

  35. Khayat D, Giroux B, Berille J, Cour V, Gerard B, Sarkany M, Bertrand P, Bizzari JP, Fotemustine in the treatment of brain primary tumors and metastases. (Review) Cancer Invest 12(4):414–420, 1994

    Article  PubMed  CAS  Google Scholar 

  36. Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE 2I, Dowell JM, Friedman AH, Friedman HS, Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma Cancer 103(2):329–338, 2005

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to X. Durando.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s11060-006-9182-5

Rights and permissions

Reprints and permissions

About this article

Cite this article

Durando, X., Thivat, E., Roché, H. et al. Cystemustine in recurrent high grade glioma. J Neurooncol 79, 33–37 (2006). https://doi.org/10.1007/s11060-005-9096-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-005-9096-7

Keywords

Navigation